CytomX Therapeutics (CTMX) Change in Cash (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Change in Cash came in at $16.2 million in Q1 2026, up 69.17% YoY from $9.6 million in Q1 2025, and up 176.89% on a QoQ basis from -$21.0 million in Q4 2025.
CytomX Therapeutics (CTMX) Change in Cash (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Change in Cash data on file, last reported at $16.2 million in Q1 2026.
- Quarterly Change in Cash rose 69.17% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.3 million (down 258.52% YoY) and the FY2025 annual result came in at -$24.9 million, down 218.55% from the prior year.
- Change in Cash grew to $16.2 million in Q1 2026, from -$21.0 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $98.6 million in Q4 2022 to a low of -$137.3 million in Q1 2023.
- A 5-year average of -$10.4 million and a median of -$2.6 million in 2024 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2024 — Change in Cash jumped 498.98% — and 2025, when it slumped 732.77%.
- Tracing CTMX's Change in Cash over 5 years: stood at $98.6 million in 2022, then sank by 108.98% to -$8.9 million in 2023, then soared by 71.49% to -$2.5 million in 2024, then tumbled by 732.77% to -$21.0 million in 2025, then surged by 176.89% to $16.2 million in 2026.
- The last three Change in Cash figures came in at $16.2 million (Q1 2026), -$21.0 million (Q4 2025), and -$14.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -11.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.60 Mn |
| Mar 31, 2026 | 16.16 Mn |
| Dec 31, 2025 | -21.02 Mn |
| Sep 30, 2025 | -14.86 Mn |
| Jun 30, 2025 | 1.44 Mn |
| Mar 31, 2025 | 9.55 Mn |
| Dec 31, 2024 | -2.52 Mn |
| Sep 30, 2024 | -2.56 Mn |
| Jun 30, 2024 | 7.06 Mn |
| Mar 31, 2024 | 19.01 Mn |
| Dec 31, 2023 | -8.85 Mn |
| Sep 30, 2023 | -31.51 Mn |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | -137.29 Mn |
| Dec 31, 2022 | 98.62 Mn |
| Sep 30, 2022 | -34.26 Mn |
| Jun 30, 2022 | -34.20 Mn |
| Mar 31, 2022 | -42.04 Mn |
| Dec 31, 2021 | -30.75 Mn |
| Sep 30, 2021 | -19.86 Mn |